FORXIGA

This brand name is authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Japan, Lithuania, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, South Africa, Spain, Tunisia, UK.

Active ingredients

The drug FORXIGA contains one active pharmaceutical ingredient (API):

1	Dapagliflozin UNII 887K2391VH - DAPAGLIFLOZIN PROPANEDIOL
	Dapagliflozin is a highly potent, selective and reversible inhibitor of SGLT2. SGLT2 is the predominant transporter responsible for reabsorption of glucose from the glomerular filtrate back into the circulation. Dapagliflozin improves both fasting and post-prandial plasma glucose levels by reducing renal glucose reabsorption leading to urinary glucose excretion.
	Read more about Dapagliflozin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
FORXIGA Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A10BK01	Dapagliflozin	A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BK Sodium-glucose co-transporter 2 (SGLT2) inhibitors
Discover more medicines within A10BK01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10011X, 11291G
BR	Câmara de Regulação do Mercado de Medicamentos	502317100031917, 502317100032017, 502317100032117, 505113120021102
CA	Health Products and Food Branch	02435462, 02435470
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	4302-MEE-0718
EE	Ravimiamet	1598597, 1598609, 1598610, 1598621, 1598632, 1598643, 1598654, 1598665, 1598676, 1598687
ES	Centro de información online de medicamentos de la AEMPS	112795007
FI	Lääkealan turvallisuus- ja kehittämiskeskus	041140, 492107, 507959, 596876
FR	Base de données publique des médicaments	67456363
GB	Medicines & Healthcare Products Regulatory Agency	216096, 216099, 368932, 368933, 374376, 374377, 374379, 376656, 376657, 379893, 381356, 381358, 381359, 389124
HK	Department of Health Drug Office	63301, 63302
IE	Health Products Regulatory Authority	18921, 18954
IL	מִשְׂרַד הַבְּרִיאוּת	7585
JP	医薬品医療機器総合機構	3969019F1027, 3969019F2023
LT	Valstybinė vaistų kontrolės tarnyba	1068363, 1068364, 1068365, 1068366, 1068367, 1068368, 1068369, 1068370, 1068371, 1068372, 1091484
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	049M2013
NL	Z-Index G-Standaard, PRK	104760, 104779
NZ	Medicines and Medical Devices Safety Authority	15029
PL	Rejestru Produktów Leczniczych	100279418, 100279424
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W62286001, W62286002, W62286003, W62286004, W62286005, W65166001, W65166002, W65166003, W65166004, W65166005
SG	Health Sciences Authority	14541P, 14542P
TN	Direction de la Pharmacie et du Médicament	8233071, 8233072
ZA	Health Products Regulatory Authority	46/21.2/0214, 46/21.2/0215